Meera Mohan
@MeeraMohanMD
Followers
1K
Following
5K
Media
28
Statuses
1K
Associate Professor of Medicine, Myeloma Clinical Faculty @MCW, Proud UAMS Alumnus @UAMS myeloma.@AACR/ ASCO Vail 2022 Alumni.
Milwaukee, WI
Joined January 2019
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma | Blood Advances | American Society of Hematology https://t.co/9iQHMBsOqz
@UAMSMyeloma
ashpublications.org
Key Points. MRD conversion occurs in 39% of MRD− MM patients and reliably predicts future relapse.MRD conversion within 10 years of diagnosis confers an in
7
20
92
The NDMM prognostic score from the IMS is out. How should we deal with it in daily practice, across laboratories with different expertises and resources? Within the European Myeloma Network we discuss this issue @Hemasphere_EHA #mmsm #MultipleMyeloma #RRMM
https://t.co/K1ceTSgTat
onlinelibrary.wiley.com
Given the evolving understanding of genetic risk factors in multiple myeloma (MM), this paper assesses whether next-generation sequencing (NGS) could complement or even replace fluorescence in situ...
1
10
15
It was really fun talking with these guys! Great discussion after the IMS meeting about bispecifics and more.
Tune in to our new episode on International #Myeloma Society 2025 Updates with key abstracts ranging from smoldering myeloma to relapsed/refractory myeloma with @AlGarfall! https://t.co/NtpYtVDUpB
0
6
12
Looking forward to going to 🇵🇱 for the first time - thanks @AJurczyszyn for the invitation and looking forward to discussing #MMsm myeloma with @H_Einsele @MorieGertz @JoshuaRichterMD @suvannasankha and more!
0
3
9
📣 Philadelphia Myeloma Roundtable, Join us! 📍 Sheraton Philadelphia University City 🕗 8:00 AM – 2:30 PM Hear from top myeloma researchers, join breakout sessions for newly diagnosed & relapsed patients, and get your questions answered in Q&A sessions! 💙 Register now:
1
2
3
Fascinated by the emerging field of spatial transcriptomics in the bone marrow. Happy to share our new editorial, co-authored with Niels Weinhold: Unlocking myeloma’s spatial world at the micrometer scale. https://t.co/UF3AEcjWjT I also recommend the new paper by Yip et al. 👍
0
5
20
Excited to share new study out today on @JCO_ASCO where we leveraged #WGS to reclassify MGUS and SMM and define the concept of "malignant transformation" @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic #mmsm 1/14
8
37
86
Following an exciting #IMS25, looking forward to synthesizing data across all #PlasmaCellDisorders for the 2nd Annual Kyle-Barlogie Symposium by @MayoClinic & @MSKCancerCenter. 📍 Minneapolis 📅October 10-11, 2025! Link: https://t.co/zDvs1a8A8C 📢Trainees: Complimentary reg!
I’ll be speaking at this meeting next week. Also speaking are @szusmani @FrancescoMaura4 @UrviShahMD @sridevirajeeve @LesokhinMD and more from @MSKCancerCenter And many of my colleagues from @MayoClinic including @MorieGertz @ADispenzieri @myelomaMD @JoselleCookMD
0
3
7
Thanks @NoopurRajeMD for mentorship, @MeeraMohanMD @KRejeski et al for excellent insights! Trials of IgG replacement with bsAbs in #MMsm should be done: IVIG vs SCIG, flat-dose vs wt-based, when to stop. But for Cycle 1 - this is like acyclovir in terms of simple safety step!
great viewpoint piece by @RahulBanerjeeMD @BloodAdvances
0
3
14
Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM
https://t.co/vu9REOKBPS 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and
21
259
885
Are you a Hem/Onc fellow, Hem/Onc PD, TCT director or faculty? Help shape the future of TCT training by completing this <2 min survey! https://t.co/nebX31OSfY
#ASHMEI #Meded #bmtsm
@ASH_hematology @HemOncFellows @OncMedEdCoP @ASTCT
0
3
7
BCJ Editors in Chief @VincentRK and Ayalew Tefferi achieve an impressive H-index of 180 at the same time!
0
6
33
TRIMM-2 study @BloodPortfolio #mmsm Talquetamab + daratumumab in RRMM showed: ✅ ORR: 71–82% (by cohort) ⏳ Median PFS: 18–23 mo ⚠️ Gr ≥3 AEs: 82% (oral AEs: 89%, incl. dysgeusia) 🛑 D/C due to AEs: 9% 💥 Active post–T-cell redirection: ORR 77% ➡️ https://t.co/HPJXQx7Vgw
2
10
37
Presented at #IMS25, now in @BloodPortfolio 👉22% of NDMM HR by new IMWG Consensus Genomic model 👉CD38 Ab & ASCT had ⬆️⬆️PFS for both SR and HR 👉If no HR genomics, ⬆️ B2M had similar outcomes as normal B2M #MMSM #MedTwitter @ASchavgoulidze 👏👏
Validation of new IMWG consensus HR genomic model in 6528 NDMM patients: 22.4% were HR, median PFS 30 months (vs. 51 months in SR). More predictive than R-ISS #mmsm #bmtsm @BloodPortfolio @ASchavgoulidze @PerrotAurore
1
8
25
Out now in @LeukemiaJnl! We compare Total Lesion Glycolysis (TLG) with Deauville Score (DS) as a PET-based response assessment metric in myeloma with extramedullary disease(EMD) @myelomaMD @VincentRK @mSMART_Myeloma @MayoRadiology
#mmsm 🧵 1/ https://t.co/7Xvgs7kVDZ
nature.com
Leukemia - Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis
3
15
44
At #IMS25, we saw the future of myeloma care taking shape, driven by science and the urgency patients feel every day. 💜 ✅ 9 abstracts presented from HealthTree Cure Hub data ✅ Patient perspectives on MRD, CAR T vs. bispecifics & decision-making ✅ CEO Jenny Ahlstrom: “If I’ve
0
4
15
🚴♀️Our team "Paraprotein Peloton: Cure Myeloma" is joining #YourVelocity to raise funds for Columbia’s @columbiacancer. Pipettes in the lab, trials in the clinic, and pedals on the road: we're powering cures together! Join/support us: https://t.co/s3tkdLYFqs
#myeloma #cancercure
velocityride.org
On October 5, I’ll be participating in Your Velocity. I’ve committed to raising crucial funds to help solve cancer at Columbia's Herbert Irving Comprehensive Cancer Center and I can’t do it without...
1
6
10
@DoctorAKrishnan is an amazing mentor, colleague and a leader of the City of Hope Myeloma @cityofhopeoc program and a national leader. Very pleased she is the SWOG chair and looking forward to the collaboration.
So proud of @DoctorAKrishnan who was just announced by @SWOGChair as chair of the @SWOG Barlogie-Salmon Myeloma Committee, taking over for @Myeloma_Doc. I’ve know Dr. Krishnan for 2 decades - you won’t find someone more perfect for this role! #SWOGonc
1
6
16
This further reinforces our @BloodAdvances viewpoint earlier this year: Use primary IVIG prophylaxis with bsAbs in myeloma #MMsm! Benefits far outweigh risks, and we now know from this #IMS25 oral that both severe infection & all-grade infection density are lower.
0
4
17
1/ #IMS25 We know that FHRMM is a function of both disease biology and T-cell function... But is FHRMM really FHRMM if the patient received suboptimal induction? 🤔 Come join us at Abstract Session 9 tomorrow morning to find out... OA-53 led by @utkarshgoel08 @DimaDanai!
#IMS25 functional high-risk myeloma (FHRMM) makes an appearance again, this time on plenary stage. We’re making progress, but still work to do - 13% of “standard” risk with new IMS/IMWG (B2M not included) still relapsed early. Better tools needed! (Tweet by @RahulBanerjeeMD)
1
2
8